State of New Jersey Common Pension Fund D purchased a new position in Arcellx, Inc. (NASDAQ:ACLX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 23,966 shares of the company’s stock, valued at approximately $1,838,000.
Other hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arcellx by 21.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,944 shares of the company’s stock valued at $161,000 after purchasing an additional 347 shares during the last quarter. abrdn plc purchased a new stake in Arcellx in the third quarter valued at about $4,242,000. China Universal Asset Management Co. Ltd. boosted its holdings in Arcellx by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,339 shares of the company’s stock worth $863,000 after acquiring an additional 4,052 shares in the last quarter. US Bancorp DE grew its stake in shares of Arcellx by 60.0% during the third quarter. US Bancorp DE now owns 7,603 shares of the company’s stock worth $635,000 after acquiring an additional 2,851 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its holdings in shares of Arcellx by 37.0% during the third quarter. Harbor Capital Advisors Inc. now owns 27,896 shares of the company’s stock valued at $2,330,000 after acquiring an additional 7,534 shares in the last quarter. 96.03% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Arcellx
In other news, insider Christopher Heery sold 10,155 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $63.79, for a total value of $647,787.45. Following the completion of the sale, the insider now owns 37,486 shares of the company’s stock, valued at $2,391,231.94. This represents a 21.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $76.97, for a total value of $115,455.00. The disclosure for this sale can be found here. Insiders sold 27,570 shares of company stock worth $1,952,095 in the last 90 days. 6.24% of the stock is owned by company insiders.
Analyst Ratings Changes
View Our Latest Stock Analysis on ACLX
Arcellx Price Performance
Arcellx stock opened at $62.65 on Wednesday. The stock has a market capitalization of $3.39 billion, a P/E ratio of -88.24 and a beta of 0.29. Arcellx, Inc. has a 12-month low of $47.88 and a 12-month high of $107.37. The firm’s 50-day moving average is $69.31 and its two-hundred day moving average is $77.56.
Arcellx Profile
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
See Also
- Five stocks we like better than Arcellx
- What is a Low P/E Ratio and What Does it Tell Investors?
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How to invest in marijuana stocks in 7 steps
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Stock Market Sectors: What Are They and How Many Are There?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Want to see what other hedge funds are holding ACLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcellx, Inc. (NASDAQ:ACLX – Free Report).
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.